Direct oral anticoagulants for the treatment of acute venous thromboembolism in patients with cancer: a meta-analysis of randomised controlled trials Source: Eur Respir J, 50 (3) 1701097; 10.1183/13993003.01097-2017 Year: 2017
Rivaroxaban versus low-molecular-weight heparin for venous thromboembolism in gastrointestinal and pancreatobiliary cancer Source: International Congress 2018 – Diagnosis, prognostication and treatment of pulmonary embolism Year: 2018
Direct oral anticoagulants and venous thromboembolism Source: Eur Respir Rev 2016; 25: 295-302 Year: 2016
Anti-Factor Xa levels correlate with recurrent venous thromboembolism and clinically relevant bleeding in patients receiving low-molecular-weight heparin. Source: International Congress 2019 – Epidemiology and management of acute pulmonary embolism Year: 2019
Prolonged anticoagulation in VTE with direct oral anticoagulants: towards an individual analysis of net clinical benefit? Source: Eur Respir J 2016; 48: 1268-1270 Year: 2016
Prospects for the prevention and treatment of venous thromboembolism Source: ISSN=1025-448x, ISBN=1-904097-31-6, page=155 Year: 2004
Anticoagulant treatment of venous thromboembolism: established and new oral agents, remaining questions Source: International Congress 2014 – Current controversies in the management of acute pulmonary embolism Year: 2014
Long-term low molecular weight heparin treatment in cancer associated venous thromboembolism patients Source: International Congress 2015 – Pulmonary circulation: pulmonary embolism and chronic thromboembolic pulmonary hypertension Year: 2015
A single centre experience of low dose direct oral anticoagulants (DOAC) after unprovoked venous thromboembolism (VTE) Source: International Congress 2019 – Epidemiology and management of acute pulmonary embolism Year: 2019
Direct oral anticoagulant therapy in patients with morbid obesity after intermediate- or high-risk pulmonary emboli Source: ERJ Open Res, 7 (1) 00554-2020; 10.1183/23120541.00554-2020 Year: 2021
A prospective study of the use of low molecular weight heparin for prevention of venous thrombo-embolism in breathless patients with limited mobility Source: Annual Congress 2009 - Intensive care unit management and outcome Year: 2009
Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment Source: Eur Respir J 2016; 48: 1369-1376 Year: 2016
Efficacy and safety of treatment with anticoagulants in patients with unprovoked venous thromboembolism in Korea Source: International Congress 2016 – Acute pulmonary embolism Year: 2016
Fixed or weight-adjusted dosis of enoxaparin as prophylaxis for venous thromboembolism in acutelly ill medical patients Source: Eur Respir J 2004; 24: Suppl. 48, 273s Year: 2004
Complications of anticoagulant therapy in patients with pulmonary thromboembolism Source: Eur Respir J 2007; 30: Suppl. 51, 604s Year: 2007
A case-control study on direct oral anticoagulants versus warfarin for acute pulmonary embolism in obese patients Source: Virtual Congress 2021 – Insights into pulmonary embolism Year: 2021
Treatment and prevention of cancer-associated venous thromboembolism Source: Virtual Congress 2021 – Pulmonary embolism: controversies in management Year: 2021
Enoxaparin versus unfractionated heparin in acute pulmonary thromboembolism Source: Eur Respir J 2002; 20: Suppl. 38, 237s Year: 2002
Efficiency of r-TPA therapy in major venous thromboembolism Source: Eur Respir J 2007; 30: Suppl. 51, 83s Year: 2007
Low-molecular-weight heparin versus unfractionated heparin in acute pulmonary thromboembolism Source: Eur Respir J 2001; 18: Suppl. 33, 381s Year: 2001